Vertex Pharmaceuticals Incorporated (VRTX) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 33/100
- 10Y CAGR
- 27.9%
- Median YoY
- 17.6%
- YoY volatility
- σ 20.2pp· choppy
- Quarters ≥ 20%
- 19 of 40
- Negative quarters
- 1
- Valuation vs own 10Y history
- P/S 11.2x · 10Y median 11.2x · 50th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 19 of 40 → 19 of 40 pts
- Steadiness (typical swing 20.2pp) → 10.6 of 25 pts
- Pace (median 17.6% YoY) → 3.5 of 20 pts
- Latest quarter (12.5% YoY) → 0 of 15 pts
- Score: 33 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 27.9% | 17.6% | 20.2pp | 19 of 40 | 1 |
| EPSEPS | — | 15.1% | 390.5pp | 14 of 32 | 7 |
| Op cash flowOperating cash flow | — | 30.6% | 99.3pp | 18 of 34 | 8 |
| EBITDAEBITDA | — | 20.1% | 2395.7pp | 16 of 32 | 7 |
| FCFFree cash flow | — | 29.8% | 152.7pp | 18 of 34 | 8 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: VRTX on the compounders surface · All compounders, ranked